BioCentury
ARTICLE | Clinical News

Enzalutamide: Phase II started

July 15, 2013 7:00 AM UTC

Medivation began an open-label, international Phase II trial to evaluate 160 mg oral enzalutamide once daily in about 80 patients. Enzalutamide is approved as Xtandi in the U.S., EU and Canada to tre...